Van Der Velde 1975.

Methods	Allocation: randomised ‐ no further details. Blinding: double ‐ identical capsules. Duration: 6 weeks ‐ preceded by 14 day drug free period. Setting: single centre.
Participants	Diagnosis: schizophrenia, acute or acute exacerbation (by 2 psychiatrists & principal investigator). N=82. Age: mean ˜ 27 years. Sex: 43 M, 33 F, 6 not reported. Exclusion: not completing 2 weeks of study medication. History: 18/82 first episode, rest onset in last 6 years.
Interventions	1. Loxapine: dose range 50‐150 mg/day. N=26. 2. Thiothixene: dose range 20‐60 mg/day. N=28. 3. Placebo. N=28. Antiparkinsonian drugs and chlorayl hydrate as required.
Outcomes	Dropped from analysis. Leaving the study early. Adverse effects. Laboratory tests. Unable to use ‐ Efficacy: (variance analyses ‐ no usable data). Global effect: CGI (no usable data). Mental state: BPRS (no usable data). Behaviour: NOSIE (no usable data). Adverse effects: Use of antiparkinsonian drugs (no data). Physiological measures: BP, EEG, pulse, temperature, weight (no data).
Notes	6 people withdrawn from analyses ‐ original group clear so ITT analysis possible.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear